Imricor Medical Systems Ltd (ASX:IMR) has banked $35 million through a two-tranche placement to further its expansion into Australia and New Zealand, commercialisation of products and a series of clinical trials, including one for the US Food and Drug Administration (FDA). The company – which focuses on developing magnetic resonance imaging (MRI)-compatible medical devices, used to carry out real-time interventional Cardiac Magnetic Resonance Imaging (iCMR) cardiac ablation procedure- said the placement had been supported by new and existing securityholders. The capital raising brought in appr…